Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.

MLA

Gopaluni, Seerapani, et al. “Rituximab versus Azathioprine as Therapy for Maintenance of Remission for Anti-Neutrophil Cytoplasm Antibody-Associated Vasculitis (RITAZAREM): Study Protocol for a Randomized Controlled Trial.” Trials, vol. 18, no. 1, Mar. 2017, p. 112. EBSCOhost, https://doi.org/10.1186/s13063-017-1857-z.

APA

Gopaluni, S., Smith, R. M., Lewin, M., McAlear, C. A., Mynard, K., Jones, R. B., Specks, U., Merkel, P. A., & Jayne, D. R. W. (2017). Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials, 18(1), 112. https://doi.org/10.1186/s13063-017-1857-z

Chicago

Gopaluni, Seerapani, Rona M Smith, Michelle Lewin, Carol A McAlear, Kim Mynard, Rachel B Jones, Ulrich Specks, Peter A Merkel, and David R W Jayne. 2017. “Rituximab versus Azathioprine as Therapy for Maintenance of Remission for Anti-Neutrophil Cytoplasm Antibody-Associated Vasculitis (RITAZAREM): Study Protocol for a Randomized Controlled Trial.” Trials 18 (1): 112. doi:10.1186/s13063-017-1857-z.